

# PUBLIKATIONSLISTE

DR. BERND WEBER, KASSEL

- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, P Geyer, **B Weber**, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Pre-existing Co-Morbidities and Co-Medications of patients undergoing Treatment of chronic HCV G1 Infection in German Real-Life**, Poster DDW Washington, 2015
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, P Geyer, **B Weber**, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Treatment of chronic HCV Genotype 1 (GT1) Infection with Boceprevir in German Real-Life: The impact of SVR on initially elevated and initially normal serum Alanine Aminotransferase (ALT) and Gamma-Glutamyl-Transpeptidase (GGT) Levels**, Poster DDW Washington, 2015
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, P Geyer, **B Weber**, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Treatment of chronic HCV Genotype 1 (GT1) Infection with Boceprevir: Frequency, Severity, Predictability and Management of anemia in German Real-Life**, Poster DDW Washington, 2015
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, P Geyer, **B Weber**, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Efficacy and safety of Boceprevir triple Therapy in previously treated patients with HCV-Genotype 1 (GT1) infection in German Real-Life**, Poster DDW Washington, 2015
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, P Geyer, **B Weber**, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Boceprevir Triple Therapy of chronic HCV Genotyp 1 (G1) infection in previously untreated patients: Efficacy, Predictability of virological response and safety in German Real-Life**, Poster DDW Washington, 2015
- Hämmig, R., Köhler, W., Bonorden-Kleij, K., **Weber, B.**, Lebentrau, K., Berthel, T., Babic-Hohnjec, L., Vollmert, C., Höpner, D., Gholami, N., Verthein, U., Haasen, C., Reimer, J. & Ruckes, C.: **Safety and Tolerability of Slow-release Oral Morphine versus Methadone in the Treatment of Opioid Dependence**, Journal of Substance Abuse Treatment (2014), doi: 10.1016/j.jsat.2014.05.012
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Treatment of Previously Untreated Patients with Chronic HCV Genotype 1 Infection with Boceprevir in German Real-Life: High End of Treatment Response > 90% in Patients with Early Virologic Response**, Poster AASLD Boston, 2014
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Renal Impairment under Triple Therapy with Boceprevir in German Real-Life: Evidence for a Pivotal Role for Peginterferon/Ribavirin Backbone, Female Gender and Age >50 Years**, Poster AASLD Boston, 2014
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Frequency and Impact of Thyroid Dysfunction on Early Virologic Response in Patients Undergoing Boceprevir Triple Therapy for HCV Genotype 1 Infection**, Poster AASLD Boston, 2014
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Low Viral Load  $\leq 400.000$  IU/mL and Normal Gamma-GT are Independent Baseline Predictors of High Early Virologic Response (EVR) Rates up to 93% in Previously Untreated Patients Undergoing Boceprevir (BOC) Triple Therapy for HCV Genotype 1 Infection in German Real-Life**, Poster AASLD Boston, 2014
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Estimated Glomerular Filtration Rate (eGFR) at Baseline Strongly Predicts the Frequency of Anemia in Patients Undergoing Boceprevir Triple Therapy in German Real-Life**, Poster AASLD Boston, 2014
- P Buggisch, H Löhner, G Teuber, H Steffens, M Kraus, C John, P Geyer, **B Weber**, T Witthöft, A Herrmann, M Hoesl, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer: **Impact of Baseline Gamma-GT on Virologic Response during Lead-In with Peginterferon/Ribavirin and Subsequent Triple Therapy with Boceprevir**, Poster AASLD Boston, 2014
- G. Teuber, P. Buggisch, H. Löhner, H. Steffens, M. Kraus, C. John, P. Geyer, **B. Weber**, T. Witthöft, A. Herrmann, M. Hoesl, U. Naumann, T. Dahhan, D. Hartmann, B. Dreher, M. Bilzer: **Treatment of previously untreated patients with chronic Hepatitis C Genotype 1 (G1) Infection in German Real - Life: Frequency and Severity of Hematological Alterations under Boceprevir Triple Therapy compared to dual Therapy**, Abstract UEG Week Wien 2014
- E. Schott, A. Schober, R. Link, **B. Weber**, A. Rieke, G. Moog, U. Spengler, R. Heyne, M.-C. Jung, G. Teuber, M. Frank Doss, M. Roessle, S. Mauss, U. Alshuth, D. Hueppe, BNG Study Group: **Adverse events and co-medication: A comparison between dual- and triple-combination therapies in genotype 1 patients with chronic hepatitis C**, Poster EASL, London 2014
- Claus Niederau; Stefan Mauss; Andreas Schober; Albrecht Stoehr; Tim Zimmermann; Michael Waizmann; Gero Moog; Stefan Pape; **Bernd Weber**; Konrad Isernhagen; Petra Sandow; Bernd Bokemeyer; Ulrich Alshuth; Hermann Steffens; Dietrich Hueppe: **Predictive factors for sustained virological response after treatment with pegylated interferon  $\alpha$ -2a and ribavirin in patients infected with HCV genotypes 2 and 3**, PLOS ONE, 2014
- Jens Reimer, Eduard Boniakowski, Christian Bachner, **Bernd Weber**, Wieland Tietje, Uwe Verthein and Stephan Walcher: **When higher doses in opioid replacement treatment are still inadequate - association to multidimensional illness severity: a cohort study**, Substance Abuse Treatment, Prevention and Policy, 2014, MS: 8742038951093102

# PUBLIKATIONSLISTE

DR. BERND WEBER, KASSEL

- **Weber B**, Ablaßmaier-Stuetzel B, Naumann U, Schleeauf D, Bachner C, Goelz J, Bannout F, Isernhagen K, Gottberg J, Forestier N, Buescher K-G, Baumgarten A, Backmund M, Alshuth U, Walcher S and the bng – study group: **Virological Efficacy of Boceprevir and Telaprevir plus Peginterferon alfa-2a/Ribavirin until Week 12 in Drug Addicted Patients with Genotype 1 Infection: First Real Life Report**, Poster-Presentation EASL, Amsterdam 2013 und Poster-Präsentation INSHU, München 2013
- Schulte B, Gonzales-Saiz F, Jeschke P, Reimer J, Schäfer I, Walcher S, **Weber B**, Verthein U.: **Die Opiate-Dosage-Adequacy-Scale (ODAS) für die Beurteilung der Angemessenheit der Buprenorphindosierung während der Opiatsubstitution**, Suchttherapie 2013 DOI: 10.1055/s-0033-1355363
- Mauss S, Lutz T, Boeker K, Link R, Moog G, Stoehr A, Baumgarten A, John C, Heyne R, Eisenbach C, Schiffelholz W, Teuber G, **Weber B**, Schott E, Hillenbrand H, Alshuth U, Hueppe D, Buggisch P: **Viral Response at Week 2 as a Predictive Factor for RVR in Chronic HCV Genotype 1 Infection Treated with Peginterferon alfa-2a (PEG) and Ribavirin (RBV)**, Poster EASL, Barcelona 2012
- Jaeckel E, Zehnter E, Lutz T, Carlebach A, Link R, John C, Teuber G, Schmidt W, Bruch H, Heyne R, Geyer P, **Weber B**, Stern M, Naumann U, Spengler U, Herold C, Stoehr A, Sandow P, Stoll S, Manns MP, bng study group: **Early Markers of Metabolic Syndrome Are Associated With Distinct HCV Genotypes, While Abnormal Glucose Tolerance Substantially Decreases the Likelihood of SVR**, Poster EASL, Barcelona 2012
- **Weber B**, Mauss S, Hey K-H, Waizmann M, Schober A, Bellmann G, Büscher K-G, Link R, Mauruschat S, Cimander KF, Breske A, Walcher S: **Substance-associated Co-morbidity During Oral Maintenance Therapy Impacts Outcome of Hepatitis C Therapy: Conjoint Analysis of Data from two German Noninterventional Cohorts**, Poster- and Oral Presentation DDW Chicago, 2011
- Gerhard Bühringer, Dresden; **Bernd Weber**, Kassel. **Erhebliche Fortschritte bei der Finanzierung ambulanter Psychotherapie bei Suchtkranken im Rahmen der Psychotherapie-Richtlinie**, Subletter 04/2011 ([www.subletter.de](http://www.subletter.de))
- Carlebach A, Mauss S, Schober A, Link R, Moog G, Hey K, Schiffelholz W, Teuber G, **Weber B**, Baumgarten A, Schmidt W, Stoehr A, Waizmann M, Isernhagen K, Alshuth U, Zehnter E, Hueppe D: **Comparison of Therapy Outcome of Patients with Drug Addiction (DA) versus Patients with Former iv Drug Use (IVDU) Treated with Peginterferon alfa-2a/Ribavirin in Real Life Setting**, Poster AASLD, Boston 2011
- Jaeckel E, Zehnter E, Lutz T, Carlebach A, Link R, John C, Hey K, Teuber G, Schmidt W, Bruch H, Heyne R, Geyer PR, **Weber B**, Stern M, Naumann U, Spengler U, Herold C, Stoehr A, Sandow P, Manns MP, Stoll S: **Pathological Glucose Tolerance and Treated Hypertension Identify HCV-Patients with Negative Prognostic Parameters for SVR**, Poster AASLD, Boston 2011
- Gardini A, Poehlke T, Reimer J, Walcher S, **Weber B**: **Kulturelle und sprachliche Validierung des ODAS (EADO) Fragebogens – eines Instrumentes zur Beurteilung der Angemessenheit der Methadondosierung im Rahmen der Substitutionstherapie Opiatabhängiger**, Suchttherapie 2010; 11: 138–145
- Jörn Schroeder-Printzen, Potsdam; **Bernd Weber**, Kassel: **Die Vertretung in der Substitutionsbehandlung**, Subletter 02/2010 ([www.subletter.de](http://www.subletter.de))
- Jörn Schroeder-Printzen, Potsdam; **Bernd Weber**, Kassel: **Einzelheiten zur „Substitutionsrichtlinie“ der BÄK**, Subletter 03/2010 ([www.subletter.de](http://www.subletter.de))
- Jörn Schroeder-Printzen, Potsdam; **Bernd Weber**, Kassel: **Grundlegende Überlegungen des Bundessozialgerichts zur Substitutionsbehandlung**, Subletter 4/2010 ([www.subletter.de](http://www.subletter.de))
- Jörn Schroeder-Printzen, Potsdam; **Bernd Weber**, Kassel: **Wie überbrücke ich rechtssicher die Weihnachtstage in der Substitutionsbehandlung?** Subletter 06/2010 ([www.subletter.de](http://www.subletter.de))
- **Bernd Weber**; Jörn Schroeder-Printzen: **Substitution und Recht. Ein rechtlicher Leitfaden für die substitutionsgestützte Behandlung Opiatabhängiger in Deutschland**, Reihe: Sucht-Therapie Special. Verlag ecomed MEDIZIN, 2009, ISBN 978-3-609-70467-8, Softcover ([www.ecomed-medizin.de](http://www.ecomed-medizin.de))
- Mathias Bastigkeit, Geschendorf; **Bernd Weber**, Kassel (beide Hrsg.): **„Suchtmedizinischen Grundversorgung“**, Thieme-Verlag, Heidelberg (Erscheinungsdatum voraussichtlich 2016/2017)



Kassel, den 24.12.2015

Dr. Bernd Weber